Загрузка...

Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach

Biomarkers predicting treatment response to the monoclonal antibody cetuximab in locally advanced head and neck squamous cell carcinomas (LAHNSCC) are lacking. We hypothesize that tumor accessibility is an important factor in treatment success of the EGFR targeting drug. We quantified uptake of cetu...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Even, Aniek J.G., Hamming-Vrieze, Olga, van Elmpt, Wouter, Winnepenninckx, Véronique J.L., Heukelom, Jolien, Tesselaar, Margot E.T., Vogel, Wouter V., Hoeben, Ann, Zegers, Catharina M.L., Vugts, Daniëlle J., van Dongen, Guus A.M.S., Bartelink, Harry, Mottaghy, Felix M., Hoebers, Frank, Lambin, Philippe
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2016
Предметы:
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5354801/
https://ncbi.nlm.nih.gov/pubmed/27965472
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13910
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!